Xantos Biomedicine Acquires the OriGene TrueClone(TM) Collection for HTP Screening

10-Aug-2004

OriGene Technologies Inc. announced Xantos Biomedicine in Germany has acquired access to their TrueClone(TM) Collection of non-redundant full-length human cDNA clones. Xantos uses its proprietary High-Throughput Cellular Screening Technology, XantoScreen(TM) and the full-length human clone collection to identify and functionally validate novel targets.

"Xantos has acquired the OriGene TrueClone(TM) Collection and integrated its large number of otherwise inaccessible transcripts to enhance the coverage and usefulness of our infrastructure for high throughput biology and drug target discovery," commented Ulrich Brinkmann PhD, Xantos CSO. "Results of this integration in a neurobiology target discovery project have been presented in Molecular & Cellular Proteomics (June 4, 2004)." Xantos applied the OriGene clone collection very successfully for the identification of novel factors involved in adipocyte differentiation and tumor angiogenesis.

"OriGene's mission is not only to build the most comprehensive collection of human full-length cDNAs, but also to make it a scientifically useful platform to enable systematic studies of human gene functions," said Karl Kovacs PhD, VP of Operations at OriGene. "We are excited with this opportunity to work with Xantos to validate this mission."

The 22,000 human full-length cDNAs in OriGene's TrueClone(TM) Collection are largely derived from cDNA libraries avoiding the artifacts associated with other clone collections isolated by PCR methods. Each cDNA clone matches an annotated mRNA reference sequence from established public domains and is housed in non-proprietary expression vectors suitable for transfection and direct in vivo or in vitro expression. The comprehensive nature of the TrueClone(TM) Collection and the uniformity and expression-readiness of the cloning vector uniquely enables a systems biology approach to high-throughput screening and functional studies.

https://www.bionity.com/en/news/39020/xantos-biomedicine-acquires-the-origene-trueclone-tm-collection-for-htp-screening.html